Ways of influencing investment on health from a regional perspective in a decentralized country

Luciana Ballini
Summary

Development of HTA in Regione Emilia-Romagna

Regional HTA and national / regional / local health policies

Relative poverty  RER ≈ 9%  (Italy=20%)
The development of HTA in ER-region

- HTA Europe - 1997-1998

2006 EUnetHTA Project (2006-2008)
2009 EUnetHTA Collaboration (2009)
2010 EUnetHTA Joint Action 1 (2010-2012)
2016 EUnetHTA Joint Action 3 (2016-2020)
Use of HTA in ER-region

Define appropriate use of technologies (critical appraisal of evidence)

Promote use in research (identification of research gaps)

Recommend innovative technologies (definition of potential added value)

2006

2017

8 Local Health Trusts
4 Teaching Hospitals
3 Research Hospitals

How to use

Whether to invest
Involving clinicians: appropriate use of technologies

Positron Emission Tomography

Regional clinical audit

Criteria endorsed by national specialty society
Involving clinicians:

use in research – promote R& D

The Tomotherapy project (2010)

3 RCTs

2 CCTs

Knowledge gaps

The da Vinci Robot project (2007)

Evidence Mapping
Involving clinicians:

**Non-Invasive Prenatal Test - 2015**

<table>
<thead>
<tr>
<th>Rationale</th>
<th>Potential added benefits</th>
</tr>
</thead>
<tbody>
<tr>
<td>Questions</td>
<td>Definition of assessment questions</td>
</tr>
<tr>
<td>Outcomes</td>
<td>Vote on importance of outcomes</td>
</tr>
<tr>
<td>Assessment</td>
<td>Systematic review for comparative</td>
</tr>
<tr>
<td>Voting</td>
<td>Recommendations</td>
</tr>
</tbody>
</table>

NIPT recommended

100 %
Involving decision makers: the regional context

Budget autonomy + responsibility of local Health Trusts/Hospitals

vs

Regional policy
Involving decision makers – HOW MANY TO BUY

**Appropriate use**

**Positron Emission Tomography**

**Recommended No. of PET scans in Region: 2**

**By 2008: 9 PET scans and >**

Regional clinical audit

---

**No. of PET scans recommended in Region: 2**

---

By 2010: 9 PET scans and >
Involving decision makers – HOW MANY TO BUY

Promote use in research


Evidence Mapping

3 RCTs
2 CCTs

Knowledge gaps

Recommended in Region: max. 3

Agenas Report 2017
Involving decision makers: the national context

Regional policy vs National policy

Luciana Ballini
Involving decision makers - HOW MUCH TO USE

Raccomandazioni su nivolumab, docetaxel, erlonitib, nel trattamento di seconda linea del NSCLC-squamoso

NSCLC-squamoso- 2° linea

R E P U B B L I C A I T A L I A N A
IN NOME DEL POPOLO ITALIANO
Il Consiglio di Stato

SENTENZA

“...rimane alle Regioni precluso stabilire, in senso riduttivo, i presupposti e i criteri di erogazione..”
Involving decision makers -

**WHETHER TO INVEST**

Innovative technologies
Non-Invasive Prenatal Test - 2015

- Rationale
- Potential added benefits
- Questions
- Definition of assessment questions
- Outcomes
- Vote on importance of outcomes
- Assessment
- Systematic review for comparative
- Voting
- Recommendations

Regional “extra LEA” or national “LEA”
The development of HTA in Italy

Spanish HTA Network

Article 15 Health Technology Assessment Network

Patto per la Salute per gli anni 2014-2016

National HTA programme in development